Peptide: difference between revisions
Diff·revision 12 → 13·23:44, 26 Oct 2024
Difference between revision 12 and revision 13 of Peptide. 3 lines changed; the page grew by 226 bytes.
| Revision 12 — 17:29, 10 Oct 2024 ReportReaderRilla (talk) correct the eutectic temperature — source gives a range 3,677 bytes ±0 | Revision 13 — 23:44, 26 Oct 2024 ComparisonCato (talk) rm the shipping recommendation — that is advice, not description 3,903 bytes +226 | ||
|---|---|---|---|
| 1 | {{Infobox concept | 1 | {{Infobox concept |
| 2 | | name = Peptide | 2 | | name = Peptide |
| + | 3 | | subtitle = Chemical class | |
| 3 | | image = peptide-chain.svg | 4 | | image = peptide-chain.svg |
| 4 | | caption = Amino acid residues joined by amide bonds between a carboxyl and an amino group. | 5 | | caption = Amino acid residues joined by amide bonds between a carboxyl and an amino group. |
| ⋮ | ⋮ | ||
| 31 | 32 | ||
| 32 | Numbering is a frequent source of confusion in the incretin literature, because GLP-1 is numbered from the N-terminus of proglucagon-derived GLP-1(1–37) while its active form begins at residue 7. The same substitution is therefore described as being at position 2 or position 8 depending on convention, which is why [[Semaglutide|semaglutide]] is described both as having Aib at position 8 and as having a substitution at the second residue of the active peptide.{{r|iupac}} | 33 | Numbering is a frequent source of confusion in the incretin literature, because GLP-1 is numbered from the N-terminus of proglucagon-derived GLP-1(1–37) while its active form begins at residue 7. The same substitution is therefore described as being at position 2 or position 8 depending on convention, which is why [[Semaglutide|semaglutide]] is described both as having Aib at position 8 and as having a substitution at the second residue of the active peptide.{{r|iupac}} |
| + | 34 | ||
| + | 35 | Non-proteinogenic residues are common in engineered peptides and are the main reason a peptide drug cannot generally be produced by biological expression. See [[Solid-phase peptide synthesis]]. | |
| 33 | 36 | ||
| 34 | == References == | 37 | == References == |